Neurocrine Submits New Drug Application for Valbenazine for Treatment of Tardive Dyskinesia

SAN DIEGO, Aug. 29, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for once-daily dosing of valbenazine in treating...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news